Browse the evidence

Adjustment for covariates differing between trial type and associated with BW reduction nullified the association between T2D status and weight loss (p = 0.93).

This suggests that addressing demographic and comorbid factors may improve weight loss outcomes in T2D patients.

GLP-1R agonists can improve cardiac contractility in human hearts.

Practitioners may consider GLP-1R agonists as a potential treatment to enhance heart contractility.

GLP-1R agonists raise cAMP levels in cardiac cells.

Understanding the role of cAMP may help in developing therapies targeting cardiac function.

Epicardial adipose tissue may contribute to arrhythmogenesis through pro-inflammatory and pro-fibrotic effects.

Addressing epicardial adipose tissue may be important in managing arrhythmias in obese patients.

Current evidence does not support a single dominant mechanism for the efficacy of GLP-1 receptor agonists.

Practitioners should consider multiple factors influencing the effectiveness of GLP-1 receptor agonists.

The DRL model decreased the time-to-therapeutic-dose by 20% in simulations.

Using a DRL agent can expedite achieving therapeutic doses for patients.

No effects of protein supplementation were observed on muscle volume, muscle strength, or return to sport (RTS).

Protein supplementation may not be beneficial during early rehabilitation for muscle strain injuries.

Further studies with larger samples and long-term follow-up are needed.

Encourage ongoing research to validate and refine strength training protocols for this population.

No significant differences in metabolic flexibility were observed between the RE+CON and RE+PRO groups.

Combining resistance exercise with either a control or high protein diet does not significantly alter metabolic flexibility outcomes.

Adipositas ist eine multifaktorielle Erkrankung mit global steigender Prävalenz.

Practitioners should recognize the multifactorial nature of obesity when addressing it in patients.

Total protein and animal protein were not associated with all-cause, CVD, or cancer mortality.

Practitioners should note that total and animal protein intake does not impact mortality risk.

Increasing levels of neurofilament light chain (NfL) are associated with worsening cognitive function and incident mild cognitive impairment or probable dementia.

Monitoring NfL levels may help in assessing cognitive decline in patients with T2D and obesity.

Increasing levels of glial fibrillary acidic protein (GFAP) are associated with worsening cognitive function and incident mild cognitive impairment or probable dementia.

Tracking GFAP levels may provide insights into cognitive health in patients with T2D and obesity.

Increasing baseline blood-based biomarker levels were not associated with any cognitive composite z score.

Baseline BBM levels may not be useful for predicting cognitive function in this population.

Wash-in and washout effects can threaten the validity of short-term dietary trials.

Researchers should consider the timing of interventions and outcomes in dietary trials to ensure validity.

Higher BMI was associated with a different airway shape, including larger minimum anteroposterior distance and smaller minimum lateral distance.

Understanding the changes in airway shape with BMI can help tailor OSA treatment strategies.

Loss-of-function mutations in the genes encoding POMC, MC3R, and MC4R can lead to early-onset obesity and developmental dysregulation.

Understanding these mutations can inform treatment strategies for obesity.

Recent studies have identified new genetic regulatory mechanisms and potential biomarker regions for the POMC gene and MC4R secondary messenger pathway associated with obesity.

These findings may lead to new diagnostic tools for obesity.

Obesity alone did not emerge as a robust predictor of major adverse cardiovascular events (MACEs).

Obesity should not be solely relied upon as a risk factor in cardiovascular assessments.

A better understanding of antidiabetic drugs' effects on skeletal muscle lipid metabolism is needed.

Future research should prioritize understanding how antidiabetic drugs affect lipid metabolism in skeletal muscle.

Obesogenic stimuli promote adipose tissue macrophages to recruit neutrophils from the bone marrow in mice.

Understanding neutrophil recruitment can inform strategies to manage inflammation in obesity.

Inhibiting neutrophil recruitment out of the bone marrow in obese mice or during weight loss reduces bone marrow myelopoiesis and adipose tissue inflammation.

Targeting neutrophil recruitment may help reduce inflammation during obesity management.

In humans with obesity, plasma neutrophil chemokines are increased and correlate with increased insulin resistance, but do not decrease with weight loss.

Monitoring neutrophil chemokines may provide insights into insulin resistance in obese patients.

Section 1115 Demonstration Waivers are currently serving as a temporary funding mechanism for nutrition-related programs.

Understanding the temporary nature of current funding can inform program planning.